Methamphetamine use disorder is associated with striatal dopaminergic deficits that have been linked to poor treatment outcomes, identifying these deficits as an important therapeutic target. Exercise attenuates methamphetamine-induced neurochemical damage in the rat brain, and a preliminary observation suggests that exercise increases striatal D2/D3 receptor availability (measured as nondisplaceable binding potential (BPND)) in patients with Parkinson’s disease. The goal of this study was to evaluate whether adding an exercise training program to an inpatient behavioral intervention for methamphetamine use disorder reverses deficits in striatal D2/D3 receptors. Participants were adult men and women who met DSM-IV criteria for methamphetamine dependence and were enrolled in a residential facility, where they maintained abstinence from illicit drugs of abuse and received behavioral therapy for their addiction. They were randomized to a group that received 1 h supervised exercise training (n=10) or one that received equal-time health education training (n=9), 3 days/week for 8 weeks. They came to an academic research center for positron emission tomography (PET) using [18F]fallypride to determine the effects of the 8-week interventions on striatal D2/D3 receptor BPND. At baseline, striatal D2/D3 BPND did not differ between groups. However, after 8 weeks, participants in the exercise group displayed a significant increase in striatal D2/D3 BPND, whereas those in the education group did not. There were no changes in D2/D3 BPND in extrastriatal regions in either group. These findings suggest that structured exercise training can ameliorate striatal D2/D3 receptor deficits in methamphetamine users, and warrants further evaluation as an adjunctive treatment for stimulant dependence.
Deficits in markers of the striatal dopaminergic system are hallmark features of substance use disorders (Broft and Martinez, 2012), and likely reflect both genetic predisposition and molecular adaptions to repeated drug exposure (Volkow and Baler, 2014). Human neuroimaging studies have shown that chronic methamphetamine users display deficits in striatal dopamine receptors (Lee et al, 2009), dopamine transporters (McCann et al, 2008), and vesicular monoamine transporters (Johanson et al, 2006).
Other studies have shown a gradual recovery of dopaminergic markers with sustained drug abstinence, with striatal dopamine transporter availability being 20% greater in subjects who were abstinent 12–17 months compared with those who were abstinent for only 6 months (Volkow et al, 2001). The rate of recovery of dopamine transporter availability varies widely between individuals, and some deficits persist long after cessation of drug use (McCann et al, 2008). In non-human primates, methamphetamine-induced decreases in striatal D2/D3 dopamine receptors persist for over 7 weeks (Groman et al, 2012), whereas similar cocaine-induced deficits persist for up to 1 year (Nader et al, 2006). There are no published reports of recovery of D2/D3 receptors with drug abstinence in human subjects.
Positron emission tomography (PET) imaging studies show that low levels of D2/D3 receptors are associated with drug use and associated behaviors (Broft and Martinez, 2012). In recently abstinent methamphetamine-dependent individuals (4–7 days), D2/D3 receptor availability is negatively associated with self-reported impulsivity (Lee et al, 2009), discounting of delayed rewards (Ballard et al, 2015), and caloric intake, suggesting that food is used as a substitute reinforcer in a reward deficiency syndrome (Zorick et al, 2012). Moreover, D2/D3 receptor availability and even more so function of the striatal element, as inferred from dopamine release, was positively associated with treatment outcomes for methamphetamine use disorder (Wang et al, 2012). Individual variation in striatal dopamine D2/D3 binding potential (BPND) has been linked to cognitive function and associated neural activity in domains such as risky decision making (Kohno et al, 2015) and response inhibition (Ghahremani et al, 2012; Robertson et al, 2015), in which stimulant abusers show deficits. Therefore, increasing signaling through D2/D3 receptors represents a potentially important therapeutic target in the care of individuals with addiction.
In rodents, exercise augmented striatal dopamine concentrations, dopamine receptor binding, and tyrosine hydroxylase mRNA (Greenwood et al, 2011; MacRae et al, 1987). Other studies have shown that wheel running attenuates methamphetamine-induced damage to serotonergic and dopaminergic terminals (Marshall and O’Dell, 2012; O’Dell et al, 2012), as well as D2/D3 dopamine receptor binding in a model of Parkinson’s disease (Vuckovic et al, 2010). Moreover, in a pilot study of four patients with early-stage Parkinson’s disease, striatal D2/D3 BPND was increased in the two patients who engaged in treadmill exercise but not in the two patients who did not (Fisher et al, 2013). Acute exercise activity, on the other hand, does not affect D2/D3 BPND in healthy subjects, as measured after 30 min of treadmill running (Wang et al, 2000).
Although it has been suggested that exercise can boost dopamine function during early abstinence from drug use (Lynch et al, 2013), the effects of chronic exercise on the dopamine system have not been studied in humans with addictions. In this study, therefore, PET was used with [18F]fallypride as a radioligand for dopamine D2/D3 receptors (Mukherjee et al, 1999) to examine the effect of an 8-week exercise training program on striatal D2/D3 receptor BPND in individuals undergoing behavioral treatment for methamphetamine addiction in a residential facility.
MATERIALS AND METHODS
Subjects recruited into this brain imaging study were concurrently participating in a larger randomized, controlled trial of exercise compared with health education for methamphetamine dependence (n=135) designed to test the impact of an 8-week aerobic exercise regimen vs an 8-week health education program on methamphetamine-dependent individuals who are receiving treatment at a residential treatment facility (Mooney et al, 2014). Those who met entry criteria and expressed interest in continuing were invited to participate in this substudy, involving brain scanning procedures. All participants continued with the regular schedule of treatment activities at the facility, including group and individual therapy and 12-step meetings. Screening to determine eligibility included a medical history, physical examination, clinical laboratory tests, and a 12-lead resting electrocardiogram (ECG). All study procedures were approved by the Institution Review Boards of the University of California Los Angeles (UCLA) and the Greater Los Angeles Veterans Affairs Health Care System. Participants were recruited to this study within 72 h of admission to the residential facility (CRI-Help, George T. Pfleger Rehabilitation Center, North Hollywood, CA) that they entered for addiction treatment. Each participant was fully informed of the benefits and risks of the study and provided written consent to participate. Eligible participants who passed the health screening procedures began the exercise or education programs 2 weeks after recruitment into the study.
Participants were required to be 18–55 years of age, to reside at the treatment center, and to meet DSM-IV-TR criteria for methamphetamine dependence as determined via the Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al, 1998). Individuals were excluded if they met criteria for any other axis 1 disorders or dependence on any other drugs of abuse besides nicotine and marijuana. All participants completed a comprehensive medical examination including a urine screen for recent drug use and pregnancy (females only). Exclusionary criteria included any musculoskeletal conditions and unstable cardiovascular, pulmonary, metabolic, or other disorders that would preclude participation in exercise training. Participants with conditions that could either interfere with the acquisition of the neuroimaging data or for whom the neuroimaging procedures would pose a potential risk were excluded (ie, implanted metal objects in the body, claustrophobia, and use of medications known to interact with D2/D3 receptors).
All participants completed a baseline maximal incremental exercise test using a symptom-limited incremental treadmill protocol described previously (Dolezal et al, 2014). Briefly, participants were asked to walk on a treadmill with gradually increasing speed and grade as long as they could. Individual performance on the baseline exercise test was used to set parameters for the training intensity of subsequent exercise sessions for each of the exercise group participants. Methamphetamine abstinence was confirmed for each participant by urinalysis upon entry to the study, on a weekly basis during the study, and immediately before all brain scanning procedures.
Exercise Training Group (EX)
Each participant randomized to the EX group participated in 1 h individualized exercise sessions 3 days/week for 8 weeks, under the supervision of an experienced exercise trainer, in the gym located within the treatment facility. Participants walked and/or jogged on a treadmill for 30 min at an intensity determined from the individual’s baseline exercise performance. Participants also completed a circuit-type resistance training program using weight machines and dumbbell free weights that included all the major muscle groups of the upper and lower body (Dolezal et al, 2014; Mooney et al, 2014).
Education Control Group (ED)
Each participant randomized to the ED group participated in small-group (<5 participants) health education sessions for ∼1 h, 3 times/week for 8 weeks. A trained counselor conducted sessions addressing a variety of health, wellness, and lifestyle topics such as healthy eating, dental care, acupressure, and cancer screening (Mooney et al, 2014). There was no guidance or encouragement to engage in exercise training, although participants in this group did have access to the in-house gym, as did all other residents. The amount of each participant’s physical activity outside the study procedures was recorded weekly by self-report as part of the larger study (Mooney et al, 2014). Time spent (min) walking, jogging, lifting weights, playing spots, or other physical activities that were not part of the exercise program of this study were recorded for each day of the week. Weekly combined additional activity totals were summed across all activities. Then, weekly combined activity totals were summed across the length of the study.
Dopamine D2/D3 receptor availability (D2/D3 BPND) was determined before and after the 8-week intervention in both EX and ED groups. D2/D3 BPND was determined using [18F]fallypride, a radioligand with high affinity for D2/D3 (Mukherjee et al, 1999) PET scanning was performed on a Philips Gemini Tru Flight PET/CT in 3D mode (FWHM 5.0 mm × 4.8 mm, Philips Electronics NV, The Netherlands). The mean administered dose [18F]fallypride was comparable between groups and across conditions (EX (mean MBq (SD): baseline 204.05 (10.61), after intervention 207.49 (8.86). ED: baseline 208.18 (8.08), after intervention 201.81 (8.83)). A CT transmission scan was performed to obtain data for measured attenuation correction. After bolus injection of [18F]fallypride (~5 mCi, specific activity 1 Ci/μmol). A total of 160 min of dynamic emission data were acquired in two 80-min blocks that were separated by a short break (<10 min) to reduce radiation exposure to the bladder wall and relieve participant discomfort. Data were reconstructed using the 3D row action maximum likelihood algorithm (3D-RAMLA). Scatter and random corrections were applied.
MRI Scanning and VOIs
MRI scanning was performed on a Siemens Trio (MPRAGE: repetition time=1.9 s, echo time=2.26 ms, voxel size=1 × 1 × 1 mm3, 176 slices), and processed using the FMRIB Software Library (FSL; http://fsl.fmrib.ox.ac.uk/fsl/index.html, Oxford University). Selected volumes of interest (VOIs) included the whole striatum and its functional subdivisions: limbic striatum, associative striatum, and sensory motor striatum. Extrastriatal VOIs for the hippocampus, amygdala, and thalamus were defined using the FSL software package and a whole striatum VOI was created by combining VOIs of the caudate, putamen, and nucleus accumbens. The functional subdivisions of the striatum (Martinez et al, 2011) and midbrain (Zald et al, 2010) were defined using published guidelines. The cerebellum was selected as an appropriate reference region (Hall et al, 1994; Ishibashi et al, 2013). A VOI was drawn manually in MNI-152 space as a bilateral region encompassing both hemispheres while avoiding the vermis. The standard space VOI was then transformed to each subject’s native MRI (Ishibashi et al, 2013).
PET Image Processing
Reconstructed [18F]fallypride PET data (2 blocks; 1 min × 80 frames) were combined into 16 frames, each consisting of the average of 10 min. PET images were motion-corrected then co-registered to the corresponding MRI (Jenkinson et al, 2002). VOI-based time–activity data were extracted for kinetic modeling using PMOD (PMOD 3.1, Zurich). Time–activity curves were fit using the simplified reference tissue model (SRTM) (Lammertsma and Hume, 1996). A volume-weighted average of k2’, estimated from high-activity regions (caudate and putamen), was computed. Time–activity curves were then refit using SRTM2 (Wu and Carson, 2002) applying the computed k2’ values to all VOIs. Binding potential referred to nondisplaceable uptake (BPND) was calculated by subtracting 1.0 from the product of R1 and k2’/k2a.
VOIs of the whole striatum and three functional striatal subdivisions were selected a priori because of the high degree of dopaminergic innervation in these regions and existing literature identifying dopaminergic transmission in these regions to be important in the neurobiology of methamphetamine dependence (Broft and Martinez, 2012; Lee et al, 2009; Wang et al, 2012). Exploratory investigations involved D2/D3 BPND measurements from other subcortical regions, specifically the amygdala, midbrain, thalamus, and hippocampus.
Group differences in baseline BPND (ED vs EX) were evaluated using independent-sample t-tests conducted in SPSS (IBM SPSS 22.0, Chicago, IL). Comparisons were made for BPND measurements from the whole striatum VOI. Group differences in BPND for functional striatal subdivisions were compared using post hoc t-tests if a significant difference was first identified using the whole-striatum VOI. Group differences in demographic variables (ED vs EX) were compared using independent-sample t-tests using SPSS (IBM SPSS 22.0). Using the same statistical tests, baseline BPND was also compared between subjects who did and those who did not complete the study.
Changes in whole striatum BPND between baseline and postintervention BPND as a function of treatment group was tested using a repeated-measures analysis of variance (ANOVA) in SPSS (IBM SPSS 22.0). Taking whole striatum BPND as the dependent variable, the main effects of time (baseline vs after intervention) and group (ED vs EX) were included in the model, and the interaction effect (time x group) was also included. The post hoc paired t-tests were used to test the changes in regional striatal BPND within each treatment group.
A total of 31 subjects (mean age 29.8±5.9 years) were recruited to participate in the brain imaging study; 16 were randomized to the EX group (10 men and 6 women) and 15 to the ED group (7 men and 8 women). All underwent PET scanning at baseline, but 12 subjects did not complete the protocol: 6 from the EX group and 6 from the ED group. Eleven of the noncompleters chose to leave the treatment facility, and one participant was withdrawn for medical reasons. Nineteen subjects underwent postintervention PET scanning after completing 8 weeks of exercise training (n=10) or the health education program (n=9).
Participants in the EX and ED groups did not differ on any of the demographic variables examined (Table 1). Most were smokers (n=29) and had completed an average of 11.8 years of education. On average, they reported using methamphetamine for ∼8.6 years, estimating that they had used methamphetamine on 20 of the 30 days preceding admission to the treatment facility. The subjects who did not complete the study did not differ from those who completed the protocol on any of the baseline demographic variables, except for years of methamphetamine use. Those who did not complete the protocol (n=12) had more years of methamphetamine use than those who completed (n=19) the protocol: mean (SD) years 14.7 (6.0) vs 8.6 (4.3); p=0.006. No relationships were observed between duration of methamphetamine use and baseline D2/D3 BPND.
Participants continued treatment as usual at the residential facility, and had similar clinical activities, social responsibilities, and daily meal options. Details of the study design and procedures have been reported previously (Mooney et al, 2014). On average, subjects completed ∼22 of 24 possible sessions, with no group difference in the number of sessions (mean (SD) completed: EX 22.2 (1.8) vs ED 22.4 (1.9) sessions). Body weight increased on average by 6.7% in the ED group after 8 weeks (p=0.020), whereas mean body weight did not change in the EX group. Additional physical activity for participants in the exercise program (75±85 min per week, mean±SD) and the education program (82±95 min) were comparable, and t-tests showed no group differences in weekly or cumulative additional physical activity levels.
Effects of EX and ED Interventions on Striatal D2/D3 Dopamine Receptor BPND
Baseline striatal D2/D3 BPND was approximately equal in all striatal regions between completing participants in the two treatment groups (Table 2). There were also no significant differences in baseline BPND in comparisons of participants who did and did not complete the study.
Results from the repeated-measures ANOVA showed a main effect of time on D2/D3 BPND (F1, 17=10.591, p=0.005), and an effect of treatment group × time interaction (F1, 17=4.135, p=0.058), yielding a trend-level effect of exercise on whole striatum BPND. The post hoc paired t-tests were conducted for exploratory purposes to investigate the regional effects of exercise in this small sample. Paired t-tests showed a significant increase in the whole striatum D2/D3 BPND in the EX group (t=3.917, p=0.004) but not in the ED group (t=0.848, p=0.421). All functional striatal subdivisions showed similar increases in the EX group by paired t-tests: limbic: t=3.04, p=0.014; associative: t=3.51, p=0.007; and sensory motor: t=3.691, p=0.005.
Participants in the EX group displayed an average 13.89% increase in D2/D3 BPND in the whole striatum whereas those in the ED group displayed an average increase of 3.13%. The EX group participants showed, on average, increases of 14.92 and 15.88% in the associative and sensory motor regions, respectively, and 7.63% in the limbic striatum (Figure 1). The ED group participants showed average increases of 4.84, 2.74 and 2.51% in the limbic, associative, and sensory motor regions of striatum, respectively (Figure 1).
Effects in Extrastriatal Regions
Exploratory investigations of D2/D3 BPND measurements in the amygdala, hippocampus, thalamus, and midbrain showed no group differences in BPND at baseline or after intervention (see Table 3). There were no significant changes from baseline at the post intervention PET scan, but thalamus BPND showed a trend-level increase in the ED group (t=2.18, p=0.060).
The present findings add to a preliminary report of an effect of exercise on striatal dopamine receptors in humans (Fisher et al, 2013), and on methamphetamine neurotoxicity in rodents (Marshall and O’Dell, 2012; O’Dell et al, 2012) by providing evidence that exercise increases striatal D2/D3 BPND in methamphetamine users. Although 8 weeks of drug abstinence in addition to behavioral treatment did not significantly change striatal D2/D3 receptor availability, addition of an exercise training program produced significant increases. These findings demonstrate that methamphetamine-associated deficits in the D2/D3 receptor system are reversible in human subjects, and that recovery of the dopamine system after chronic drug use can be facilitated with exercise training.
A deficit in striatal D2/D3 dopamine receptor binding is a common feature across substance use disorders (Bonci et al, 2013; Broft and Martinez, 2012). In stimulant dependence, this deficit is linked to treatment success rates (Martinez et al, 2011; Wang et al, 2012) and measures of impulsivity (Lee et al, 2009) and decision making (Ballard et al, 2015). Although these observations suggest that augmenting signaling at D2/D3 receptors may be an effective therapeutic target in substance use disorders, dopamine agonist therapy has shown limited success in improving treatment outcomes for stimulant dependence (Ling et al, 2006). Given the intricate biphasic signaling motif of the dopamine system via D1/D5 and D2/D3 receptor-mediated pathways (Gerfen and Surmeier, 2011), it is possible that indirect dopamine agonists would have a larger effect on D1/D5 over D2/D3 receptor signaling, thus disrupting the balance between striatal dopaminergic pathways. This effect would likely be further compounded in patients with D2/D3 receptor deficits, such as those seen in drug addictions (Broft and Martinez, 2012). Moreover, pharmacological treatment with nonselective D2/D3 receptor agonists may have untoward effects by augmenting D3 vs D2 receptor signaling. Notably, stimulant users show greater D3 receptor availability in the limbic striatum compared with healthy control subjects (Boileau et al, 2012). Therefore, nonpharmacologic approaches, such as structured exercise training, that augment dopaminergic signaling in physiologically relevant ways may be useful in treating those with substance use disorders.
Several lines of evidence suggest that high levels of striatal D2/D3 dopamine receptors may be protective for an individual against drug addiction. For example, unaffected family members of those with alcohol use disorders display higher D2/D3 receptor availability than affected family members, and higher D2/D3 receptor availability than nonrelated healthy control subjects, supporting the hypothesis that high levels of D2/D3 receptors may protect against alcoholism (Volkow et al, 2006). PET studies of stimulant use in humans show an inverse relationship between D2/D3 receptor availability and positive subjective response to intravenous methylphenidate administration. Individuals with high D2/D3 receptor availability report more unpleasant subjective effects, suggesting that they may be less vulnerable to stimulant abuse (Volkow et al, 1999). Moreover, striatal D2/D3 receptor availability in drug-naive rhesus monkeys is negatively correlated with the amount of drug taken by animals when trained to self-administer cocaine (Nader et al, 2006). Finally, rats exhibit decreased alcohol self-administration after being subjected to an adenoviral-mediated increase in striatal D2 receptor expression (Thanos et al, 2001).
In animal models, exercise produces the most pronounced effects on striatal dopaminergic markers in the dopamine-depleted compared with nondepleted striatum. In the MPTP animal model of Parkinson’s disease, 6 weeks of treadmill exercise produces larger increases in D2/D3 BPND in animals treated with MPTP than those treated with saline (Vuckovic et al, 2010). In rodent models of methamphetamine-induced dopamine depletion, exercise increases striatal levels of dopamine transporter and tyrosine hydroxylase in the methamphetamine-treated animals, with only minimal effects in saline-treated animals (O’Dell et al, 2012). Analogously, exercise increased D2/D3 BPND by ~80% in two patients with early-stage Parkinson’s disease, whereas it only increased D2/D3 BPND by ~9% in a healthy control subject (Fisher et al, 2013). Although healthy control subjects were not examined in this investigation, exercise-induced increases in D2/D3 receptors observed here were confined only to regions that show dopaminergic deficits in stimulant users (Lee et al, 2009; Volkow et al, 2001).
Hypofunction of the striatal dopaminergic system occurs during abstinence from stimulant use and is associated with anhedonia, negative affect, and drug craving (Volkow and Baler, 2014). Methamphetamine-dependent individuals report symptoms of depression and drug craving (Zorick et al, 2010). Results from the larger clinical trial (Mooney et al, 2014) in which all subjects included in this study were enrolled showed significant effects of the exercise regimen to improve symptoms of depression and anxiety (Rawson et al, 2015). The neuroimaging findings presented here suggest that exercise-induced increases in D2/D3 BPND may contribute to these behavioral effects, but direct examination of this relationship in the small neuroimaging subsample failed to detect any significant associations between improvements in ratings of affect and changes in D2/D3 dopamine receptor BPND. Additional research is needed to identify the neurobiological mechanisms that underlie exercise-induced amelioration of negative affect in stimulant users.
Although the molecular effects of aerobic exercise are incompletely understood, exercise increases levels of neurotrophic factors and enhances neurogenesis, immune function, and neuroplasticity (Cotman and Berchtold, 2002). The mechanisms by which exercise induces upregulation of D2/D3 receptors have been investigated in animal models of striatal dopaminergic injury, modeling Parkinson’s disease physiology. In rodents, wheel running after stimulant exposure produces significant changes in gene transcription factors capable of modulating dopaminergic neurotransmission in the mesolimbic pathways (Greenwood et al, 2011; Zlebnik et al, 2014), and wheel running attenuates MPTP-induced damage to dopaminergic cells in wild-type mice, but not in BDNF (+/−) knockdown mice (Gerecke et al, 2012). Similarly, BDNF receptor antagonists blocked the effects of treadmill running against damage to dopaminergic neurons, as indicated by preserved levels of tyrosine hydroxlase activity, in a rat model of Parkinson’s disease using striatal injection of 6-hydroxydopamine (Real et al, 2013).
Some limitations of this study warrant mention. The first relates to the relatively small size of the sample and the fact that findings may not generalize to all methamphetamine users or to those who are not exposed to exercise in a treatment setting. The size of this sample also limits the degree to which potential sex-dependent effects of exercise can be examined in this study (Lynch et al, 2013). Generalizability of the findings may be compromised by exclusion of individuals with Axis I disorders, other than methamphetamine dependence, because such psychiatric comorbidity is common among methamphetamine users.
In addition, although cigarette use was controlled during scan days, subjects continued to smoke throughout the study. As part of the larger study that included the work presented here, the number of cigarettes smoked per week as indicated by self-report was recorded (Mooney et al, 2014). Although participants in the ED group smoked slightly more cigarettes than those in the EX group at baseline (average cigarettes per week: 40±13.6 in the EX group and 55.3±9.8 in the ED group) and after completing the program (average cigarettes per week: 46±13.9 in the EX group and 69±13.9 in the ED group), t-tests showed there were no significant group differences at either time point. No effect of a group by time point interaction on the weekly number of cigarettes smoked was detected.
Another limitation of the study is the imperfect selectivity of [18F]fallypride that has nearly equal affinity for D2 and D3 dopamine receptors in vivo (Mukherjee et al, 1999) and cannot therefore distinguish between them. Thus, BPND measurements primarily reflect a combination of signals from D2 and D3 receptors. [18F]fallypride also binds to both isoforms of the D2 receptor (D2S and D2L), and therefore does not distinguish between pre- and postsynaptic D2 receptors. Similarly, D2/D3 receptor BPND estimates made using [18F]fallypride are sensitive to competition from intrasynaptic dopamine. Of relevance is the low (5–10%) test–retest variation in BPND measurements made using [18F]fallypride (Dunn et al, 2013; Fujita et al, 2006), and the observation that administration of α-methyl-p-tyrosine to reduce brain concentrations of dopamine has no effect on [18F]fallypride binding in healthy subjects (Cropley et al, 2008).
Although the focus of this investigation is the dopaminergic system, exercise has many effects on other neurotransmitter systems, including the serotonin, glutamate, and opioid systems (Greenwood et al, 2011). In addition, the effects of exercise on physiological systems outside of the brain are numerous, including cardiovascular, immune, and endocrine systems (Hillman et al, 2008). Earlier findings from a different subsample of the same clinical trial of exercise and methamphetamine dependence (Mooney et al, 2014) showed that exercise training improved heart rate variability, an index of autonomic nervous system balance, that is abnormal in methamphetamine users (Dolezal et al, 2014). Investigations to assess the degree to which exercise-induced changes in physiological measures are related to changes in neurobiological indices would prove clinically useful as a method to assess disease severity (Devos et al, 2003), or to monitor response to treatment and progression of recovery.
Our findings contribute to a growing literature identifying the therapeutic benefits of exercise in health and disease (Hillman et al, 2008), and also in the treatment of substance abuse (Lynch et al, 2013). Exercise is gaining attention as a complement to traditional pharmacological and psychotherapeutic treatments. Therefore, investigating the effects of exercise in patients with neuropsychiatric disorders featuring dopaminergic dysfunction, such as Parkinson’s disease (Dagher and Robbins, 2009), drug addictions (Bonci et al, 2013), and attention deficit disorder (Volkow et al, 2011), is of increasing clinical relevance. Understanding the molecular mechanisms by which exercise affects dopaminergic signaling in patients with stimulant use disorders may produce new clinical approaches to enhance treatment outcomes for addictions and other related neuropsychiatric disorders.
FUNDING AND DISCLOSURE
The authors declare no conflict of interest. Dr Cooper reports personal fees from Astra Zeneca, Boehringer-Ingelheim, eResearch Technologies, Equinox Health Clubs, Forest, GlaxoSmithKline, Pulmonx, Spriration, and Sunovion; and research funding from Amgen, Equinox Health Clubs and Spiration, all unrelated to this work.